Table 4.

List of BAC/PAC clones showing recurrent high copy number gains and homozygous losses in lymphoma type


Clone name*

Cytogenetic position

Gain/loss, no. patients

Amplification/homozygous loss, no. patients

Gene§
Gain     
    RP3-510D11   1p36.22   12   2  H6PD, LOC440558 
    RP5-888M10   1p36.21   11   2  VPS13D 
    RP5-1177E19   1p36.21   9   2  PRDM2 
    RP11-233K4   6p25.3   18   2  IRF4 
    RP11-498D18   7p22.2   12   2  CARMA1,GNA12 
    RP5-911H5   7q21.2   22   2  ANKIB1 
    RP11-736C20   7q21.2   23   2  CALCR 
    RP11-148A10   7q22.2   26   2  LHFPL3 
    RP11-77E2   7q22.3   25   2  DLD, LAMB1, LAMB4 
    RP11-573B16   7q31.1   25   2   —  
    RP11-9C22   7q31.33   25   2  SND1 
    RP11-66F23   7q31.33   24   2  NYD-SP18, CALU, OPN1SW, DKFZP434G156, FLNC, ATP6V1F, LOC375616 
    RP11-35B6   7q31.33   24   2  KIAA0828, FAM40B 
    RP11-233L24   7q33   21   2   —  
    RP4-659J6   7q33   24   2  ZC3HDC1, KIAA1718 
    RP11-188A12   7q33   20   2   —  
    RP11-796I2   7q35   17   2  PRKAG2, LOC441301, GALNTL5 
    RP11-476H24   7q36.2   18   2  DPP6 
    RP11-691F21   7q36.3   18   2  LOC285889 
    RP11-452C13   7q36.3   16   2  PTPRN2 
    RP11-1127D7   14q32.2   21   2  FLJ25773,RPL3P4,BCL11B 
Loss     
    RP1-101M23   6q21   12   2  PRDM1 
    RP11-149I2   9p21.3   14   2  MTAP, CDKN2A,CDKN2B,NSGX 
    RP11-214L15   9p21.3   7   2   —  
    RP11-468C2   9p21.3   5   2   —  
    RP11-461N23
 
13q32.1
 
24
 
2
 
GPR18, PHGDHL1, EBI2
 

Clone name*

Cytogenetic position

Gain/loss, no. patients

Amplification/homozygous loss, no. patients

Gene§
Gain     
    RP3-510D11   1p36.22   12   2  H6PD, LOC440558 
    RP5-888M10   1p36.21   11   2  VPS13D 
    RP5-1177E19   1p36.21   9   2  PRDM2 
    RP11-233K4   6p25.3   18   2  IRF4 
    RP11-498D18   7p22.2   12   2  CARMA1,GNA12 
    RP5-911H5   7q21.2   22   2  ANKIB1 
    RP11-736C20   7q21.2   23   2  CALCR 
    RP11-148A10   7q22.2   26   2  LHFPL3 
    RP11-77E2   7q22.3   25   2  DLD, LAMB1, LAMB4 
    RP11-573B16   7q31.1   25   2   —  
    RP11-9C22   7q31.33   25   2  SND1 
    RP11-66F23   7q31.33   24   2  NYD-SP18, CALU, OPN1SW, DKFZP434G156, FLNC, ATP6V1F, LOC375616 
    RP11-35B6   7q31.33   24   2  KIAA0828, FAM40B 
    RP11-233L24   7q33   21   2   —  
    RP4-659J6   7q33   24   2  ZC3HDC1, KIAA1718 
    RP11-188A12   7q33   20   2   —  
    RP11-796I2   7q35   17   2  PRKAG2, LOC441301, GALNTL5 
    RP11-476H24   7q36.2   18   2  DPP6 
    RP11-691F21   7q36.3   18   2  LOC285889 
    RP11-452C13   7q36.3   16   2  PTPRN2 
    RP11-1127D7   14q32.2   21   2  FLJ25773,RPL3P4,BCL11B 
Loss     
    RP1-101M23   6q21   12   2  PRDM1 
    RP11-149I2   9p21.3   14   2  MTAP, CDKN2A,CDKN2B,NSGX 
    RP11-214L15   9p21.3   7   2   —  
    RP11-468C2   9p21.3   5   2   —  
    RP11-461N23
 
13q32.1
 
24
 
2
 
GPR18, PHGDHL1, EBI2
 
*

List of BAC clones from p telomere to q telomere are listed for each chromosome number.

Gain was defined as log2 ratio +0.2 to +1.0, loss as log2 ratio -1.0 to -0.2.

Amplification was defined as log2 ratio greater than +1.0 and homozygous loss as log2 ratio less than -1.0.

§

All of the genes located on the BAC/PAC clones. If there were any oncogenes in the clone adjacent to the amplified or lost one, they were listed.

The names of genes located in the BAC clones adjacent to RP11-1127D7 are listed. BCL11B is 0.3 Mb telomeric to RP11-1127D7.

These genes have been implicated in lymphoid malignancies.17,21 

Close Modal

or Create an Account

Close Modal
Close Modal